Crohn’s disease
Polpharma Biologics and Fresenius Kabi partner to develop treatment for ulcerative colitis and Crohn’s disease
August 5, 2025Mergers and Acquisitions Corporate, Crohn’s disease, Fresenius Kabi, Gastrointestinal tract, Polpharma Biologics, ulcerative colitis
Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for the commercialisation of PB016, a proposed biosimilar to …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
August 3, 2025Research and Development Crohn’s disease, Immunology, Lilly UK, autoimmune disease, immunology
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in the UK is at a …
NICE recommends NHS use of mirikizumab for Crohn’s disease
July 11, 2025Medical Communications, Research and Development Crohn’s disease, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency, NHS, National Institute for Health and Care Excellence (NICE), bowel disease, clinical trial
Eli Lilly (Lilly) has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab (omvoh) for …
EVerZom receives €3m funding from French government to industrialise exosome technology
June 18, 2025Research and Development BpiFfrance, Corporate, Crohn’s disease, EVerZom, France 2030, French government, age-related disorders, exosome therapy, neurodegenerative disease
EVerZom, a French biopharma company focused on exosome-based therapies, has announced it has received €3m in funding as part of …
NICE recommends mirikizumab (Omvoh ▼) for previously treated moderately to severely active Crohn’s disease 1
May 30, 2025Research and Development Crohn’s disease, Eli Lilly and Company, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency (MHRA)(, NHS England and Wales, National Institute for Health and Care Excellence (NICE), Omvoh, inflammatory bowel disease (IBD), mirikizumab
In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at …
European Commission approves Johnson & Johnson’s Crohn’s disease therapy
May 12, 2025Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation
The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …
Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment
May 22, 2024Medical Communications Crohn’s disease, Eli Lilly, Endocrinology, clinical trial, mirikizumab
Eli Lilly has announced results from its pivotal phase 3 VIVID-1 study, which assessed patients with moderately to severely active …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
October 4, 2023Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …
Research shows neonatal stem cells could be used as treatment for Crohn’s disease
July 31, 2023Research and Development Crohn’s disease, Gastrointestinal tract, Stem cells, gastrointestinal
Recent studies from the Ann & Robert H Lurie Children’s Hospital in Chicago have discovered that human neonatal cardiac-derived mesenchymal …
Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis
May 11, 2020Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis
The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …
Janssen shows off Phase 3b interim data for Stelara in Crohn’s disease
February 18, 2020Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma
Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara (ustekinumab) in the treatment …
Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease
February 17, 2020Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma
Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a …
Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease
July 23, 2019Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma
Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …
Takeda scores Japanese Entyvio approval in Crohn’s disease
May 22, 2019Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma
Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …
Stem cells could ‘reset’ immune system in Crohn’s disease patients
August 8, 2018Research and Development Crohn’s disease, Stem cells, crohn's disease, trials
A clinical trial led by researchers at Queen Mary University, London is looking into ways in which patients with Crohn’s …
